サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1751082

原発性免疫不全症の世界市場レポート 2025年

Primary Immunodeficiency Disorders Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.06円
原発性免疫不全症の世界市場レポート 2025年
出版日: 2025年06月17日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

原発性免疫不全症市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR6.8％で95億1,000万米ドルに成長します。予測期間の成長は、皮下療法の採用拡大、ヘルスケアアクセスの改善、研究開発の活発化、効率的な治療に対する需要の高まり、免疫グロブリン補充療法のニーズの高まりに起因しています。予測期間における主な動向としては、バイオテクノロジーの進歩、革新的な遺伝子治療や生物製剤、遺伝子検査や個別化医療の進歩、遺伝子治療や遺伝子検査における継続的な進歩などが挙げられます。

自己免疫疾患の有病率の増加は、原発性免疫不全症市場の成長を促進すると予測されています。自己免疫疾患は、免疫系が身体の健康な細胞や組織を誤って攻撃し、それらを外敵と認識することで発生します。この誤った免疫反応により、様々な臓器やシステムで炎症と損傷が引き起こされます。自己免疫疾患の増加は、環境要因、遺伝的素因、ライフスタイルの変化などが複雑に絡み合っているためと考えられています。これらの病気は、免疫調節を乱し、免疫細胞を攻撃することで、免疫反応を弱めたり、損なわせたりして原発性免疫不全症を引き起こします。例えば、2024年11月、ドイツの双方向オンライン・プラットフォームであるVersorgungsatlas.deのデータによると、2022年、7,324万1,305人の被保険者のうち、630万4,340人が少なくとも1つの自己免疫疾患と診断され、有病率は8.61％でした。このような自己免疫疾患の有病率の増加は、原発性免疫不全症市場拡大の主要な促進要因です。

原発性免疫不全症市場の主要企業は、免疫機能を改善することで患者の予後を向上させるため、免疫グロブリン静注療法（IVIG療法）などの先進療法の開発に注力しています。IVIG療法は、ドナーの血漿由来の免疫グロブリン（抗体）を静脈注射によって患者の血流に直接投与するものです。例えば、2024年6月、スペインに本社を置くヘルスケア企業Grifols社は、静脈内免疫グロブリン（IVIg）療法であるYimmugoのFDA承認を取得しました。この新しい無糖のすぐに使えるIgG溶液はヒト血漿由来で、静脈内投与を目的としています。米国では、一次抗体欠乏症患者における代替療法として承認されています。Yimmugoは、免疫不全患者をサポートする抗体代替療法を提供し、より安全で効果的な感染防御ソリューションを提供することで、グリフォルス社の血漿ベースの治療ポートフォリオを強化します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界原発性免疫不全症PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の原発性免疫不全症市場：成長率分析
  • 世界の原発性免疫不全症市場の実績：規模と成長, 2019-2024
  • 世界の原発性免疫不全症市場の予測：規模と成長, 2024-2029, 2034F
  • 世界原発性免疫不全症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の原発性免疫不全症市場：疾患別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 抗体欠乏症
  • 細胞性免疫不全症
  • 先天性免疫疾患
  • その他の病気
  • 世界の原発性免疫不全症市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 免疫グロブリン補充療法
  • 抗生物質療法
  • 幹細胞と骨髄移植
  • 遺伝子治療
  • その他の治療法
  • 世界の原発性免疫不全症市場診断タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 遺伝子検査
  • 血液検査
  • フローサイトメトリー
  • その他の診断の種類
  • 世界の原発性免疫不全症市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 専門クリニック
  • 在宅ケア設定
  • 調査機関
  • 世界の原発性免疫不全症市場抗体欠損症のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 分類不能型免疫不全症（CVID）
  • IgA欠乏症
  • IgGサブクラス欠損症
  • 特異的抗体欠損症
  • 世界の原発性免疫不全症市場細胞性免疫不全症の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 重症複合免疫不全症（SCID）
  • T細胞欠損症
  • ディジョージ症候群
  • ウィスコット・アルドリッチ症候群
  • 世界の原発性免疫不全症市場、自然免疫疾患の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 慢性肉芽腫性疾患（CGD）
  • 補体欠損症
  • Toll様受容体欠損症
  • チェディアック・東症候群
  • 世界の原発性免疫不全症市場その他の疾患のサブセグメンテーション（種類別）、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 高IgM症候群
  • 高IgE症候群
  • 毛細血管拡張性運動失調症
  • 症候群性特徴を伴う複合免疫不全症

第7章 地域別・国別分析

  • 世界の原発性免疫不全症市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の原発性免疫不全症市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 原発性免疫不全症市場：競合情勢
  • 原発性免疫不全症市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Takeda Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
    • CSL Behring Overview, Products and Services, Strategy and Financial Analysis
    • Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Grifols SA
  • Octapharma
  • Kedrion Biopharma
  • Miltenyi Biotec
  • LFB Group
  • Clinigen Limited
  • ADMA Biologics Inc.
  • Bio Products Laboratory Ltd
  • BD Biosciences
  • Cellectis SA
  • Florencia Healthcare
  • X4 Pharmaceuticals Inc.
  • Amber Lifesciences
  • bluebird bio Inc.
  • Chengdu Rongsheng Pharmaceutical Co Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 原発性免疫不全症市場2029：新たな機会を提供する国
  • 原発性免疫不全症市場2029：新たな機会を提供するセグメント
  • 原発性免疫不全症市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34935

Primary immunodeficiency disorders (PIDs) are inherited conditions that impair the immune system, making individuals more susceptible to infections, autoimmune diseases, and certain cancers. Early diagnosis and identification of PIDs are critical for effective treatment, infection prevention, and improving patient health through therapies such as immunoglobulin replacement or bone marrow transplants.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The main types of primary immunodeficiency disorders include antibody deficiencies, cellular immunodeficiencies, innate immune disorders, and others. Antibody deficiencies occur when the immune system is unable to produce sufficient antibodies, which are responsible for detecting and neutralizing harmful pathogens. Treatments available include immunoglobulin replacement therapy, antibiotic treatment, stem cell or bone marrow transplants, gene therapy, and other methods. Diagnostic approaches involve genetic testing, blood tests, flow cytometry, and other techniques, which are typically applied in hospitals, specialty clinics, home care settings, and research institutions.

The primary immunodeficiency disorders market research report is one of a series of new reports from The Business Research Company that provides primary immunodeficiency disorders market statistics, including the primary immunodeficiency disorders industry's global market size, regional shares, competitors with a primary immunodeficiency disorders market share, detailed primary immunodeficiency disorders market segments, market trends and opportunities, and any further data you may need to thrive in the primary immunodeficiency disorders industry. This primary immunodeficiency disorders market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The primary immunodeficiency disorders market size has grown strongly in recent years. It will grow from$6.84 billion in 2024 to $7.32 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth during the historic period can be attributed to the rising incidence of primary immunodeficiency disorders, increased awareness among healthcare professionals, growing demand for effective treatments, higher research funding, and an increased focus on pediatric care.

The primary immunodeficiency disorders market size is expected to see strong growth in the next few years. It will grow to$9.51 billion in 2029 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to the growing adoption of subcutaneous therapies, improved healthcare access, robust research and development, a higher demand for efficient treatments, and an increasing need for immunoglobulin replacement therapy. Major trends in the forecast period include advancements in biotechnology, innovative gene therapies and biologics, progress in genetic testing and personalized medicine, and ongoing advancements in gene therapy and genetic tests.

The increasing prevalence of autoimmune diseases is anticipated to drive the growth of the primary immunodeficiency disorders market. Autoimmune diseases occur when the immune system erroneously attacks the body's healthy cells and tissues, perceiving them as foreign invaders. This misdirected immune response leads to inflammation and damage across various organs and systems. The rise in autoimmune diseases is attributed to a complex mix of environmental factors, genetic predispositions, and lifestyle changes. These diseases can cause primary immunodeficiency disorders by disrupting immune regulation and attacking immune cells, resulting in weakened or impaired immune responses. For example, in November 2024, data from Versorgungsatlas.de, an interactive online platform in Germany, revealed that in 2022, among 73,241,305 insured individuals, 6,304,340 were diagnosed with at least one autoimmune disease, resulting in a raw prevalence rate of 8.61%. This increasing prevalence of autoimmune diseases is a key driver behind the expansion of the primary immunodeficiency disorders market.

Leading companies in the primary immunodeficiency disorders market are focusing on the development of advanced therapies such as intravenous immunoglobulin (IVIG) therapy to enhance patient outcomes by improving immune function. IVIG therapy involves administering immunoglobulins (antibodies) derived from donor plasma directly into a patient's bloodstream through an IV. For instance, in June 2024, Grifols, a healthcare company based in Spain, received FDA approval for Yimmugo, an intravenous immunoglobulin (IVIg) therapy. This new sugar-free, ready-to-use IgG solution, derived from human blood plasma, is intended for intravenous administration. It was approved in the U.S. for substitution therapy in patients with primary antibody deficiency syndromes. Yimmugo provides antibody replacement to support individuals with immune deficiencies, enhancing Grifols' portfolio of plasma-based treatments by offering a safer and more effective solution to protect against infections.

In April 2022, Grifols, S.A., a pharmaceutical company based in Spain, acquired Biotest AG for an undisclosed amount. This acquisition is aimed at accelerating growth and fostering innovation by expanding Grifols' plasma-derived medicines portfolio and strengthening its global market presence. Biotest AG, a biotechnology company based in Germany, specializes in plasma proteins and biological drugs.

Major players in the primary immunodeficiency disorders market are Pfizer Inc., Thermo Fisher Scientific Inc., Takeda Pharmaceuticals, CSL Behring, Baxter International Inc., Grifols SA, Octapharma, Kedrion Biopharma, Miltenyi Biotec, LFB Group, Clinigen Limited, ADMA Biologics Inc., Bio Products Laboratory Ltd, BD Biosciences, Cellectis SA, Florencia Healthcare, X4 Pharmaceuticals Inc., Amber Lifesciences, bluebird bio Inc., and Chengdu Rongsheng Pharmaceutical Co Ltd.

North America was the largest region in the primary immunodeficiency disorders market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in primary immunodeficiency disorders report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the primary immunodeficiency disorders market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary immunodeficiency disorders market consists of revenues earned by entities by providing services such as immunoglobulin therapy, rehabilitation and support programs, educational and advocacy services, and personalized treatment plans. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary immunodeficiency disorders market also includes sales of vaccines, antibiotics, antifungals, and small molecule drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Immunodeficiency Disorders Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary immunodeficiency disorders market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary immunodeficiency disorders ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary immunodeficiency disorders market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Disease: Antibody Deficiency; Cellular Immunodeficiency; Innate Immune Disorders; Other Diseases
  • 2) By Treatment: Immunoglobulin Replacement Therapy; Antibiotic Therapy; Stem Cell And Bone Marrow Transplantation; Gene Therapy; Other Treatments
  • 3) By Diagnostic Type: Genetic Testing; Blood Testing; Flow Cytometry; Other Diagnostic Types
  • 4) By End-User: Hospitals; Specialty Clinics; Homecare Settings; Research Institutions
  • Subsegments:
  • 1) By Antibody Deficiency: Common Variable Immune Deficiency (CVID); IgA Deficiency; IgG Subclass Deficiency; Specific Antibody Deficiency
  • 2) By Cellular Immunodeficiency: Severe Combined Immunodeficiency (SCID); T-Cell Deficiency; DiGeorge Syndrome; Wiskott-Aldrich Syndrome
  • 3) By Innate Immune Disorders: Chronic Granulomatous Disease (CGD); Complement Deficiencies; Toll-like Receptor Deficiencies; Chediak-Higashi Syndrome
  • 4) By Other Diseases: Hyper IgM Syndrome; Hyper IgE Syndrome; Ataxia-Telangiectasia; Combined Immunodeficiencies With Syndromic Features
  • Companies Mentioned: Pfizer Inc.; Thermo Fisher Scientific Inc.; Takeda Pharmaceuticals; CSL Behring; Baxter International Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Immunodeficiency Disorders Market Characteristics

3. Primary Immunodeficiency Disorders Market Trends And Strategies

4. Primary Immunodeficiency Disorders Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Primary Immunodeficiency Disorders Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Primary Immunodeficiency Disorders PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Primary Immunodeficiency Disorders Market Growth Rate Analysis
  • 5.4. Global Primary Immunodeficiency Disorders Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Primary Immunodeficiency Disorders Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Primary Immunodeficiency Disorders Total Addressable Market (TAM)

6. Primary Immunodeficiency Disorders Market Segmentation

  • 6.1. Global Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Antibody Deficiency
  • Cellular Immunodeficiency
  • Innate Immune Disorders
  • Other Diseases
  • 6.2. Global Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Immunoglobulin Replacement Therapy
  • Antibiotic Therapy
  • Stem Cell And Bone Marrow Transplantation
  • Gene Therapy
  • Other Treatments
  • 6.3. Global Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Genetic Testing
  • Blood Testing
  • Flow Cytometry
  • Other Diagnostic Types
  • 6.4. Global Primary Immunodeficiency Disorders Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Specialty Clinics
  • Homecare Settings
  • Research Institutions
  • 6.5. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Antibody Deficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Common Variable Immune Deficiency (CVID)
  • IgA Deficiency
  • IgG Subclass Deficiency
  • Specific Antibody Deficiency
  • 6.6. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Cellular Immunodeficiency, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Severe Combined Immunodeficiency (SCID)
  • T-Cell Deficiency
  • DiGeorge Syndrome
  • Wiskott-Aldrich Syndrome
  • 6.7. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Innate Immune Disorders, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Chronic Granulomatous Disease (CGD)
  • Complement Deficiencies
  • Toll-like Receptor Deficiencies
  • Chediak-Higashi Syndrome
  • 6.8. Global Primary Immunodeficiency Disorders Market, Sub-Segmentation Of Other Diseases, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hyper IgM Syndrome
  • Hyper IgE Syndrome
  • Ataxia-Telangiectasia
  • Combined Immunodeficiencies With Syndromic Features

7. Primary Immunodeficiency Disorders Market Regional And Country Analysis

  • 7.1. Global Primary Immunodeficiency Disorders Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Primary Immunodeficiency Disorders Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Immunodeficiency Disorders Market

  • 8.1. Asia-Pacific Primary Immunodeficiency Disorders Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Immunodeficiency Disorders Market

  • 9.1. China Primary Immunodeficiency Disorders Market Overview
  • 9.2. China Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Immunodeficiency Disorders Market

  • 10.1. India Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Immunodeficiency Disorders Market

  • 11.1. Japan Primary Immunodeficiency Disorders Market Overview
  • 11.2. Japan Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Immunodeficiency Disorders Market

  • 12.1. Australia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Immunodeficiency Disorders Market

  • 13.1. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Immunodeficiency Disorders Market

  • 14.1. South Korea Primary Immunodeficiency Disorders Market Overview
  • 14.2. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Immunodeficiency Disorders Market

  • 15.1. Western Europe Primary Immunodeficiency Disorders Market Overview
  • 15.2. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Immunodeficiency Disorders Market

  • 16.1. UK Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Immunodeficiency Disorders Market

  • 17.1. Germany Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Immunodeficiency Disorders Market

  • 18.1. France Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Immunodeficiency Disorders Market

  • 19.1. Italy Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Immunodeficiency Disorders Market

  • 20.1. Spain Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Immunodeficiency Disorders Market

  • 21.1. Eastern Europe Primary Immunodeficiency Disorders Market Overview
  • 21.2. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Immunodeficiency Disorders Market

  • 22.1. Russia Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Immunodeficiency Disorders Market

  • 23.1. North America Primary Immunodeficiency Disorders Market Overview
  • 23.2. North America Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Immunodeficiency Disorders Market

  • 24.1. USA Primary Immunodeficiency Disorders Market Overview
  • 24.2. USA Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Immunodeficiency Disorders Market

  • 25.1. Canada Primary Immunodeficiency Disorders Market Overview
  • 25.2. Canada Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Immunodeficiency Disorders Market

  • 26.1. South America Primary Immunodeficiency Disorders Market Overview
  • 26.2. South America Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Immunodeficiency Disorders Market

  • 27.1. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Immunodeficiency Disorders Market

  • 28.1. Middle East Primary Immunodeficiency Disorders Market Overview
  • 28.2. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Immunodeficiency Disorders Market

  • 29.1. Africa Primary Immunodeficiency Disorders Market Overview
  • 29.2. Africa Primary Immunodeficiency Disorders Market, Segmentation By Disease, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Primary Immunodeficiency Disorders Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Primary Immunodeficiency Disorders Market, Segmentation By Diagnostic Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Immunodeficiency Disorders Market Competitive Landscape And Company Profiles

  • 30.1. Primary Immunodeficiency Disorders Market Competitive Landscape
  • 30.2. Primary Immunodeficiency Disorders Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Thermo Fisher Scientific Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Takeda Pharmaceuticals Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. CSL Behring Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Baxter International Inc. Overview, Products and Services, Strategy and Financial Analysis

31. Primary Immunodeficiency Disorders Market Other Major And Innovative Companies

  • 31.1. Grifols SA
  • 31.2. Octapharma
  • 31.3. Kedrion Biopharma
  • 31.4. Miltenyi Biotec
  • 31.5. LFB Group
  • 31.6. Clinigen Limited
  • 31.7. ADMA Biologics Inc.
  • 31.8. Bio Products Laboratory Ltd
  • 31.9. BD Biosciences
  • 31.10. Cellectis SA
  • 31.11. Florencia Healthcare
  • 31.12. X4 Pharmaceuticals Inc.
  • 31.13. Amber Lifesciences
  • 31.14. bluebird bio Inc.
  • 31.15. Chengdu Rongsheng Pharmaceutical Co Ltd

32. Global Primary Immunodeficiency Disorders Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Immunodeficiency Disorders Market

34. Recent Developments In The Primary Immunodeficiency Disorders Market

35. Primary Immunodeficiency Disorders Market High Potential Countries, Segments and Strategies

  • 35.1 Primary Immunodeficiency Disorders Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Primary Immunodeficiency Disorders Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Primary Immunodeficiency Disorders Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer
  • 250617_r34935_Primary_Immunodeficiency_Disorders_GMR_2025